Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model

Neuro-Oncology

Volumn 10, Issue 1, 2008, Pages 19-31

  King, Gwendalyn D ^a   Ghulam Muhammad, A K M ^a   Curtin, James F ^a   Barcia, Carlos ^a   Puntel, Mariana ^a   Liu, Chunyan ^a   Honig, Sarah B ^a   Candolfi, Marianela ^a   Mondkar, Sonali ^a   Lowenstein, Pedro R ^a   Castro, Maria G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Flt3L; Glioblastoma; HSV1 TK; Immunotherapy; Multiple tumor

Indexed keywords

ADENOVIRUS VECTOR; FLT3 LIGAND; GANCICLOVIR; SODIUM CHLORIDE; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA; HEMISPHERE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT INDICATION; TREATMENT OUTCOME; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; MALE; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; RATS; RATS, INBRED LEW; THYMIDINE KINASE; TRANSPLANTATION, ISOGENEIC;

EID: 39149132784     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2007-045     Document Type: Article

References (83)

1. Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas: a histologic study of large hemisphere sections. Cancer. 1987;60:1519-1531.
2. Silbergeld DL, Rostomily RC, Alvord EC Jr. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol. 1991;10:179-185.
3. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405-1409.
4. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1997-2001. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2004.
5. Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21:1624-1636.
6. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5:881-887.
7. Ikeda K, Wakimoto H, Ichikawa T, et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication- conditional herpes simplex virus mutant. J Virol. 2000;74:4765-4775.
8. Kramm CM, Rainov NG, Sena-Esteves M, et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther. 1996;7:1989-1994.
9. Kramm CM, Rainov NG, Sena-Esteves M, et al. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther. 1996;7:291-300.
10. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 2005;12:647-654.
11. Furumoto K, Soares L, Engleman EG, et al. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest. 2004;113:774-783.
12. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
13. Lowenstein PR. Dendritic cells and immune responses in the central nervous system. Trends Immunol. 2002;23:70.
14. Broder H, Anderson A, Kremen TJ, et al. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J Neurooncol. 2003;64:21-30.
15. Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90:1115-1124.
16. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515-5525.
17. Yamanaka R, Yajima N, Abe T, et al. Dendritic cell-based glioma immunotherapy (review). Int J Oncol. 2003;23:5-15.
18. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973-4979.
19. Curtin JF, King GD, Barcia C, et al. FMS-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol. 2006;176:3566-3577
20. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953-1962.
21. Shurin MR, Pandharipande PP, Zorina TD, et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 1997;179:174-184.
22. Shaw SG, Maung AA, Steptoe RJ, et al. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol. 1998;161:2817-2824.
23. Averbook BJ, Schuh JL, Papay R, et al. Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother. 2002;25:27-35.
24. Chen K, Braun S, Lyman S, et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 1997;57:3511-3516.
25. Wang A, Braun SE, Sonpavde G, et al. Antileukemic activity of Flt3 ligand in murine leukemia. Cancer Res. 2000;60:1895-1900.
26. Borges L, Miller RE, Jones J, et al. Synergistic action of FMS-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol. 1999;163:1289-1297.
27. Lynch DH, Andreasen A, Maraskovsky E, et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 1997;3:625-631.
28. Peron JM, Esche C, Subbotin VM, et al. FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol. 1998;161:6164-6170.
29. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble FMS-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther. 2004;10:1071-1084.
30. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005;65:7194-7204.
31. Candolfi M, Curtin JF, Xiong WD, et al. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther. 2006;14:371-381.
32. Maleniak TC, Darling JL, Lowenstein PR, et al. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Ther. 2001;8:589-598.
33. Candolfi M, Curtin JF, Nichols WS, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol. 2007; 85:133-48.
34. Southgate T, Kingston P, Castro MG. Gene transfer into neural cells in vivo using adenoviral vectors. In: Gerfen CR, McKay R, Rogawski MA, Sibley DR, Skolnick P, eds. Current Protocols in Neuroscience. New York: John Wiley; 2000:4.23.1-4.23.40.
35. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med. 1999;5:1256-1263.
36. Thomas CE, Schiedner G, Kochanek S, et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA. 2000;97:7482-7487
37. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther. 2003;8:846-852.
38. Dion LD, Fang J, Garver RI Jr. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods. 1996;56:99-107
39. Cotten M, Baker A, Saltik M, et al. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther. 1994;1:239-246.
40. Maizel JV Jr, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968;36:115-125.
41. Puntel M, Curtin JF, Zirger JM, et al. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum Gene Ther. 2006;17:531-544.
42. Lowenstein PR, Thomas CE, Umana P, et al. High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. Methods Enzymol. 2002;346:292-311.
43. Umana P, Gerdes CA, Stone D, et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol. 2001;19:582-585.
44. Candolfi M, Kroeger KM, Pluhar GE, et al. Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery. 2007;60:167-178.
45. Candolfi M, Pluhar GE, Kroeger KM, et al. Optimization of adenoviral vector mediated expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro-oncology. 2007;9:245-58.
46. Simek S, Byrnes A, Bauer S. FDA perspective on the use of the adenovirus reference material. Bioprocessing. 2002;31:40-42.
47. Brunetti-Pierri N, Palmer DJ, Beaudet AL, et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther. 2004;15:35-46.
48. Muruve DA, Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther. 1999;10:965-976.
49. Muruve DA, Cotter MJ, Zaiss AK, et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol. 2004;78:5966-5972.
50. Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001;3:708-722.
51. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001;3:697-707
52. Lin J, Cai W. Effect of vimentin on reactive gliosis: in vitro and in vivo analysis. J Neurotrauma. 2004;21:1671-1682.
53. Pekny M, Johansson CB, Eliasson C, et al. Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. J Cell Biol. 1999;145:503-514.
54. Wilhelmsson U, Li L, Pekna M, et al. Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci. 2004;24:5016-5021.
55. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther. 2004;10:967-972.
56. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50:337-344.
57. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11:2389-2401.
58. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160-4167
59. El Andaloussi A, Sonabend AM, Han Y, et al. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia. 2006;54:526-535.
60. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006;12:4294-4305.
61. Heimberger AB, Crotty LE, Archer GE, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol. 2000;103:16-25.
62. Jiang H, Gomez-Manzano C, Alemany R, et al. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia. 2005;7:48-56.
63. Kambara H, Saeki Y, Chiocca EA. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res. 2005;65:11255-11258.
64. Kuwashima N, Nishimura F, Eguchi J, et al. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol. 2005;175:2730-2740.
65. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175-180.
66. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579-592.
67. Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6:1474-1480.
68. Yang WQ, Senger D, Muzik H, et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res. 2003;63:3162-3172.
69. Colak A, Goodman JC, Chen SH, et al. Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther. 1995;6:1317-1322.
70. Vincent AJ, Esandi MD, van Someren G, et al. Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene. J Neurosurg. 1996;85:648-654.
71. Yang WQ, Senger DL, Lun XQ, et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther. 2004;11:1579-1589.
72. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2177-2185.
73. Urch CE, George AJ, Stevenson GT, et al. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin. Int J Cancer. 1991;47:909-915.
74. Endo T, Toda M, Watanabe M, et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther. 2002;9:142-148.
75. Nakano K, Todo T, Chijiiwa K, et al. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther. 2001;3:431-437.
76. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000;2:324-329.
77. Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999;10:385-393.
78. Rewers AB, Redgate ES, Deutsch M, et al. A new rat brain tumor model: glioma disseminated via the cerebral spinal fluid pathways. J Neurooncol. 1990;8:213-219.
79. Bi W, Kim YG, Feliciano ES, et al. An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther. 1997;4:246-252.
80. Dilber MS, Abedi MR, Bjorkstrand B, et al. Suicide gene therapy for plasma cell tumors. Blood. 1996;88:2192-2200.
81. Perez-Cruet MJ, Trask TW, Chen SH, et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res. 1994;39:506-511.
82. Vile RG, Castleden S, Marshall J, et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer. 1997;71:267-274.
83. Wilson KM, Stambrook PJ, Bi WL, et al. HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch Otolaryngol Head Neck Surg. 1996;122:746-749.